Top ▲

AT2 receptor

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 35

Nomenclature: AT2 receptor

Family: Angiotensin receptors

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 363 Xq23 AGTR2 angiotensin II receptor type 2 49,90
Mouse 7 363 X 16.71 cM Agtr2 angiotensin II receptor, type 2 35
Rat 7 363 Xq34 Agtr2 angiotensin II receptor, type 2 90
Previous and Unofficial Names Click here for help
MRX88 | angiotensin receptor 2 | angiotensin II type 2 receptor | AT2R | AT2-R | AT2 receptor | Agtr2 | angiotensin II receptor, type 2 | angiotensin II receptor
Database Links Click here for help
Specialist databases
GPCRDB agtr2_human (Hs), agtr2_mouse (Mm), agtr2_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Orphanet
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Angiotensin II type 2 receptor with ligand.
PDB Id:  6JOD
Ligand:  angiotensin II
Resolution:  3.2Å
Species:  Human
References:  4
Natural/Endogenous Ligands Click here for help
angiotensin-(1-7) {Sp: Human, Mouse, Rat}
angiotensin II {Sp: Human, Mouse, Rat}
angiotensin III {Sp: Human, Mouse, Rat}

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[125I]CGP42112 Peptide Ligand is labelled Ligand is radioactive Hs Full agonist 10.6 pKd 21,96-97
pKd 10.6 (Kd 2.51x10-11 M) [21,96-97]
angiotensin III {Sp: Human, Mouse, Rat} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 10.4 pKd 18,21,96
pKd 10.4 [18,21,96]
angiotensin II {Sp: Human, Mouse, Rat} Peptide Approved drug Click here for species-specific activity table Ligand is endogenous in the given species Hs Full agonist 10.2 pKd 21,84,96
pKd 10.2 [21,84,96]
[p-aminoPhe6]ang II Peptide Rn Full agonist 9.1 – 9.4 pKd 21,86
pKd 9.1 – 9.4 (Kd 7.9x10-10 – 3.9x10-10 M) [21,86]
[125I][Sar1,Ile8]Ang-II Peptide Click here for species-specific activity table Ligand is labelled Ligand is radioactive Rn Full agonist 7.8 – 8.8 pKd 88
pKd 7.8 – 8.8 (Kd 1.74x10-8 – 1.7x10-9 M) [88]
angiotensin A {Sp: Human} Peptide Click here for species-specific activity table Hs Agonist 8.6 pKi 107
pKi 8.6 (Ki 2.3x10-9 M) [107]
novokinin Peptide Hs Agonist 8.1 pKi 106
pKi 8.1 (Ki 7.35x10-9 M) [106]
compound 21 [PMID: 22802221] Small molecule or natural product Immunopharmacology Ligand Rn Full agonist 5.6 – 5.8 pEC50 94
pEC50 5.6 – 5.8 [94]
compound 21 [PMID: 22802221] Small molecule or natural product Immunopharmacology Ligand Hs Full agonist 4.8 pEC50 94
pEC50 4.8 [94]
angiotensin A {Sp: Human} Peptide Click here for species-specific activity table Hs Agonist 9.9 pIC50 44
pIC50 9.9 [44]
CGP42112 Peptide Hs Full agonist 9.6 pIC50 9
pIC50 9.6 (IC50 2.33x10-10 M) [9]
angiotensin-(1-7) {Sp: Human, Mouse, Rat} Peptide Ligand is endogenous in the given species Hs Agonist 6.6 pIC50 9
pIC50 6.6 (IC50 2.46x10-7 M) [9]
View species-specific agonist tables
Agonist Comments
The natural ligands Ang II and Ang III do not distinguish between the AT1 and AT2 receptors. CGP42112 behaves like an AT1 antagonist at high concentration (Ki 1.7 µM) [11,18]. It was previously thought that Ang I was a natural ligand for AT2R, but this is incorrect. The binding of tissue expressing exclusively the AT2 receptor is not affected by GTP or its analogues [10]. In contrast, an AT2 receptor sensitive to GTPgS and pertussis toxin has been identified in rat brain [91].
β-Amino acid substitution of Ang III congeners for AT2R are reported: β-Arg2Ang III (IC50 2060 nM), β-Val3Ang III (IC50 2350 nM), β-Tyr4Ang III (IC50 1.82 nM), β-Pro7Ang III (IC50 0.47 nM) and β-Phe8Ang III (IC50 20.3 nM); IC50 values derived using HEK293 cells expressing hAT2R. These are specific AT2R agonists [51].
NP-6A4, a selective peptide agonist for AT2R (activity not reported) was shown to reduce aortic stiffness [78].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
PD123319 Small molecule or natural product Hs Antagonist 8.7 – 9.2 pKd 21,23,99
pKd 8.7 – 9.2 (Kd 1.99x10-9 – 6.3x10-10 M) [21,23,99]
saralasin Peptide Rn Antagonist 9.0 pIC50 17
pIC50 9.0 [17]
PD123177 Small molecule or natural product Rn Antagonist 8.5 – 9.5 pIC50 16-17,24
pIC50 8.5 – 9.5 (IC50 3.16x10-9 – 3.2x10-10 M) [16-17,24]
olodanrigan Small molecule or natural product Primary target of this compound Hs Antagonist 8.5 – 9.3 pIC50 28,74,83
pIC50 8.5 – 9.3 [28,74,83]
olodanrigan Small molecule or natural product Rn Antagonist 7.5 pIC50 83
pIC50 7.5 (IC50 2.95x10-8 M) [83]
View species-specific antagonist tables
Antagonist Comments
Saralasin is a non specific antagonist, which does not distinguish the AT1 and AT2 receptors [17].
Immunopharmacology Comments
AT2 receptors have been have been identified on human immunocompetent cells, and selective AT2 receptor activation stimulates an anti-inflammatory effect (reduces production of pro-inflammatory cytokines TNFα, IL-6, and IL-10 after LPS challenge) in human monocytes [59]. Experimental work indicates that AT1 and AT2 receptors can modulate the inflammatory NFκB pathway [25-26], and AT2 receptors play a role in the recruitment of inflammatory cells. Accumulating evidence suggests that regulation of the mutually antagonistic angiotensin receptors AT1 and AT2 is an essential process in the control of inflammation and that an imbalance between these two receptors has pathophysiological potential [82]. Existing anti-hypertensive drugs could be used to investigate the effect of manipulating the angiotensin system on a variety of diseases.
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0006954 inflammatory response IEA
Immuno Process:  Cytokine production & signalling
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gi/Go family Phospholipase A2 stimulation
Other - See Comments
Comments:  The AT2 receptor appear to bind to Gia2 or Gia3 [113].
Depending on the tissues, activation of the AT2 receptor
1) stimulates Tyr and Ser/Thr phosphatases (MKP-1, PP2A, SHP-1) and protein dephosphorylation,
2) regulates the nitric-oxide-cGMP system
3) stimulates phospholipase A2, release arachidonic acid and activates the Na+/HCO3 symporter [19,39,68]
4) inhibits autophagy [72]
5) modulates sympatho-excitation in hypertrophy-heart failure model [31].

Ligand-independent AT2 action results in the induction of apoptosis.

Constitutive signal transduction of AT2 [63]:
1) increased bradykinin and iNOS protein expression in VSMCs [45]
2) stimulation of apoptosis in prostate cancer cells [55]
3) increased bradykinin release in mouse coronary artery endothelial cells [116].

G-protein independent signalling: AT2 does not require phosphorylation or heterotrimeric Gαβγ protein to be active [27].
References:  33,56,113
Secondary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gi/Go family Other - See Comments
Comments:  Activation of the AT2 receptor leads to MAP kinase inactivation, opening of delayed-rectifier K channel and closing of T-type Ca channels [13,117]

Intracellular storage of AT2R [63].

While antagonism of AT1 mediated signal and function were generally observed, there are several exceptions and conflicting findings (cardiac hypertrophy, etc). Potential mechanisms of the interference include interaction and/or binding between AT2 and AT1 or competing AngII binding.
References: 
Tissue Distribution Click here for help
Non pregnant uterus, heart, lung, kidney, brain, spinal cord, failing heart, remodeling vessels, skin, atretic ovarian follicle
Species:  Human
Technique:  Immunocytochemistry, RT-PCR, microarray expression
References:  15,19,36,42,48,71
The expression is developmentally regulated: foetus >> adult; adrenal medulla > inferior olive, brain >>heart, kidney, ovary, myometrium, endothelial cells, adventitia, pancreas.
Expression in adult brainstem> fetus; fetus skin > adult.
Expression is largely in the cerebellum.

Liver and pituitary appear devoid of AT2 receptors.
Species:  Rat
Technique:  Northern blotting.
References:  19,23,53,95,112
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Nitric oxide formation and increased cGMP
Species:  Rat
Tissue:  Kidney, heart
Response measured:  cGMP
References:  32,79-80
Inhibition of cell growth leading to apoptosis
Species:  Rat
Tissue:  Confluent and quiescent neonatal cardiomyocyte, R3T3 fibroblast or PC12W pheochromocytoma cell lines
Response measured:  Radiolabelled thymidine incorporation, DNA fragmentation, Bcl2/Bax;
References:  24,38,105
Physiological Functions Click here for help
Vasodilation (still controversial)
Species:  Rat
Tissue:  Vessel
References:  19,47,58,62,65
Vascular hypertrophy and fibrosis (controversial)
Species:  Rat
Tissue:  Not specified
References:  19,58,62,65
Neuronal cell differentiation and nerve regeneration
Species:  Rat
Tissue:  NG108-15, PC12W
References:  19,30,57
Diuresis and natriuresis (controversial)
Species:  Mouse
Tissue:  AT2 KO mice
References:  81
Increased cGMP and NO
Species:  Human
Tissue:  Kidney, coronary artery, aorta, heart, neurite
References:  14,19,32,47,52,58,62,65,77,79-80,85,98,108,114
Inhibition of cell growth and stimulation of apoptosis in vitro and in vivo
Species:  Human
Tissue:  PC12W, VSMC, endothelial cells, cardiomyocytes, R3T3 fibroblast, heart (contraversial), kidney
References:  8,12,19,22,58,62,64-65,69,87,93,104-105
AT2 receptor stimulation counteracts AT1 receptor-mediated vasoconstriction
Species:  Human
Tissue:  Coronary microarteries
References:  6
Decrease of dopamine synthesis
Species:  Rat
Tissue:  Striatum
References:  60
AT2R and MTUS1 cooperate to trans-inactivate receptor tyrosine kinases (inhibition of insulin, FGF, EGF-induced ERK2, DNA synthesis, insulin receptor autophosphorylation) (controversial)
Species:  Mouse
Tissue:  CHO cells, VSMCs, COS-1 cells
References:  67
Physiological Consequences of Altering Gene Expression Click here for help
AGTR2 overexpression:
No effect on cardiac hypertrophy or attenuation of cardiac remodeling and of perivascular fibrosis, stimulation of collagen synthesis in SMC and mesangial cells but inhibition in fibroblasts, increased bradykinin and nitric oxide formation. Over expression of the AT2 receptor down-regulated the AT1 receptor.
Species:  Rat
Tissue: 
Technique:  Transgenesis.
References:  1-2,34,40-41,43,61,75-76,81,89,100-103
AGTR2 deletion:
No gross anatomical defect or deformity; increase in basal blood pressure, increased sensitivity (vasopressor response) to injected Ang II, delay in vascular smooth muscle differentiation, attenuation of exploratory behavior, stimulation of dipsogenesis, reduced fibrosis and collagen expression, increased or reduced cardiac and vascular remodeling, anti-diuresis and anti-natriuresis, increased anti-inflammatory and pro-atherosclerotic mediators.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  45,52,61,92,108
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003962 abnormal adrenaline level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003962 abnormal adrenaline level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0000818 abnormal amygdala morphology PMID: 11384784 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0004184 abnormal baroreceptor physiology PMID: 12154115 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000130 abnormal cancellous bone morphology PMID: 19004830 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0001560 abnormal circulating insulin level PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0005667 abnormal circulating leptin level PMID: 15793237 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0005416 abnormal circulating protein level PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0005416 abnormal circulating protein level PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003963 abnormal corticosterone level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003963 abnormal corticosterone level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0006319 abnormal epididymal fat pad morphology PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0002078 abnormal glucose homeostasis PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0004082 abnormal habenula morphology PMID: 11384784 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0003921 abnormal heart left ventricle morphology PMID: 12390955 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001629 abnormal heart rate PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001629 abnormal heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0001629 abnormal heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0001629 abnormal heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0001629 abnormal heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0001629 abnormal heart rate PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0008263 abnormal hippocampus CA1 region morphology PMID: 11384784 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0008265 abnormal hippocampus CA2 region morphology PMID: 11384784 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0008267 abnormal hippocampus CA3 region morphology PMID: 11384784 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003953 abnormal hormone level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003953 abnormal hormone level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0000521 abnormal kidney cortex PMID: 9551401 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000527 abnormal kidney development PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000527 abnormal kidney development PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0005555 abnormal kidney excretion PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd
MGI:87966  MP:0005555 abnormal kidney excretion PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0002135 abnormal kidney morphology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0002135 abnormal kidney morphology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0002136 abnormal kidney physiology PMID: 10620200  9551401 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd
MGI:87966  MP:0002136 abnormal kidney physiology PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0006312 abnormal kidney sodium excretion PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd
MGI:87966  MP:0006312 abnormal kidney sodium excretion PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0002118 abnormal lipid homeostasis PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0000278 abnormal myocardial fiber morphology PMID: 10930448 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003964 abnormal noradrenaline level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003964 abnormal noradrenaline level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001944 abnormal pancreas morphology PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001944 abnormal pancreas morphology PMID: 19033539 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0008872 abnormal physiological response to xenobiotic PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0008872 abnormal physiological response to xenobiotic PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0010009 abnormal piriform cortex morphology PMID: 11384784 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0005325 abnormal renal glomerulus morphology PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0005325 abnormal renal glomerulus morphology PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0005325 abnormal renal glomerulus morphology PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0005325 abnormal renal glomerulus morphology PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0005529 abnormal renal vascular resistance PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd
MGI:87966  MP:0005529 abnormal renal vascular resistance PMID: 10620200 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0004129 abnormal respiratory quotient PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 18497303 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
involves: 129S1/Sv * 129X1/SvJ * FVB/N
MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 7477266 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 10373225 
Agtr1atm1Afu|Agtr2tm1Gsb Agtr1atm1Afu/Agtr1atm1Afu,Agtr2tm1Gsb/Y
mixed
MGI:87964  MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 12388241 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 15793237 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0000230 abnormal systemic arterial blood pressure PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0000832 abnormal thalamus morphology PMID: 11384784 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0000187 abnormal triglyceride level PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003672 abnormal ureter development PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003672 abnormal ureter development PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000534 abnormal ureter morphology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000534 abnormal ureter morphology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000516 abnormal urinary system morphology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000516 abnormal urinary system morphology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0005502 abnormal urinary system physiology PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0005502 abnormal urinary system physiology PMID: 10024874 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0005592 abnormal vascular smooth muscle morphology PMID: 10373225 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0001622 abnormal vasculogenesis PMID: 10373225 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0000250 abnormal vasoconstriction PMID: 10373225 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0000343 altered response to myocardial infarction PMID: 12624001 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0000343 altered response to myocardial infarction PMID: 12390955 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0003141 cardiac fibrosis PMID: 10930448  12390955 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0005602 decreased angiogenesis PMID: 14597675 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0005534 decreased body temperature PMID: 7477267 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0001262 decreased body weight PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0001262 decreased body weight PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0001262 decreased body weight PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0001262 decreased body weight PMID: 18497303 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
involves: 129S1/Sv * 129X1/SvJ * FVB/N
MGI:87966  MP:0003912 decreased drinking behavior PMID: 7477266 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0003910 decreased eating behavior PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001417 decreased exploration in new environment PMID: 7477267 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0003916 decreased heart left ventricle weight PMID: 12390955 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0005333 decreased heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0005333 decreased heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0005333 decreased heart rate PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0005333 decreased heart rate PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0002834 decreased heart weight PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0002834 decreased heart weight PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0002834 decreased heart weight PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0002834 decreased heart weight PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0002834 decreased heart weight PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0002834 decreased heart weight PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
SWR.129P2-Agtr2
MGI:87966  MP:0004502 decreased incidence of chemically-induced tumors PMID: 16140932 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0003918 decreased kidney weight PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0004876 decreased mean systemic arterial blood pressure PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0004876 decreased mean systemic arterial blood pressure PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0004876 decreased mean systemic arterial blood pressure PMID: 18497303 
Agtr1atm1Unc|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87966  MP:0004876 decreased mean systemic arterial blood pressure PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0009109 decreased pancreas weight PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0009109 decreased pancreas weight PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0004486 decreased response of heart to induced stress PMID: 10930448 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001489 decreased startle reflex PMID: 7477267 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0010182 decreased susceptibility to weight gain PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0009133 decreased white fat cell size PMID: 15793237 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0002753 dilated heart left ventricle PMID: 12624001 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000519 hydronephrosis PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0000519 hydronephrosis PMID: 10024874 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0000519 hydronephrosis PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0000519 hydronephrosis PMID: 18497303 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
involves: 129S1/Sv * 129X1/SvJ * FVB/N
MGI:87966  MP:0001402 hypoactivity PMID: 7477266 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003043 hypoalgesia PMID: 7477267 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0005601 increased angiogenesis PMID: 14597675 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0005605 increased bone mass PMID: 19004830 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0009347 increased cancellous bone thickness PMID: 19004830 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001748 increased circulating adrenocorticotropin level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001748 increased circulating adrenocorticotropin level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001745 increased circulating corticosterone level PMID: 12218346 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0001745 increased circulating corticosterone level PMID: 12218346 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
involves: 129S1/Sv * 129X1/SvJ * FVB/N
MGI:87966  MP:0003911 increased drinking behavior PMID: 12388241 
Agtr1atm1Afu|Agtr2tm1Gsb Agtr1atm1Afu/Agtr1atm1Afu,Agtr2tm1Gsb/Y
mixed
MGI:87964  MGI:87966  MP:0003911 increased drinking behavior PMID: 12388241 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0004889 increased energy expenditure PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003459 increased fear-related response PMID: 7477267 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0002891 increased insulin sensitivity PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0004875 increased mean systemic arterial blood pressure PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0004875 increased mean systemic arterial blood pressure PMID: 12154115 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0004875 increased mean systemic arterial blood pressure PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0004875 increased mean systemic arterial blood pressure PMID: 18497303 
Agtr1btm1Cof|Agtr2tm1Tin Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87965  MGI:87966  MP:0004875 increased mean systemic arterial blood pressure PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0008873 increased physiological sensitivity to xenobiotic PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0008873 increased physiological sensitivity to xenobiotic PMID: 12154115 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0008873 increased physiological sensitivity to xenobiotic PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0005659 increased resistance to diet-induced obesity PMID: 15793237 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0009763 increased sensitivity to induced morbidity/mortality PMID: 12624001 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0009763 increased sensitivity to induced morbidity/mortality PMID: 12390955 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0002842 increased systemic arterial blood pressure PMID: 7477267 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0002842 increased systemic arterial blood pressure PMID: 12154115 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0006143 increased systemic arterial diastolic blood pressure PMID: 7477267 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
involves: 129S1/Sv * 129X1/SvJ * FVB/N
MGI:87966  MP:0006144 increased systemic arterial systolic blood pressure PMID: 12388241 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0006144 increased systemic arterial systolic blood pressure PMID: 7477267 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0003025 increased vasoconstriction PMID: 11714657 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0009130 increased white fat cell number PMID: 15793237 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003585 large ureter PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003585 large ureter PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003334 pancreas fibrosis PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003334 pancreas fibrosis PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0009150 pancreatic acinar cell atrophy PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0009150 pancreatic acinar cell atrophy PMID: 19033539 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0008528 polycystic kidney PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0008528 polycystic kidney PMID: 10024874 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0002082 postnatal lethality PMID: 18497303 
Agtr1atm1Unc|Agtr1btm1Cof|Agtr2tm1Tin Agtr1atm1Unc/Agtr1atm1Unc,Agtr1btm1Cof/Agtr1btm1Cof,Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87964  MGI:87965  MGI:87966  MP:0002082 postnatal lethality PMID: 18497303 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003446 renal hypoplasia PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003446 renal hypoplasia PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd
MGI:87966  MP:0003215 renal interstitial fibrosis PMID: 9551401 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003604 single kidney PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003604 single kidney PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0010725 thin interventricular septum PMID: 10930448 
Agtr2tm1Tin Agtr2tm1Tin/Y
B6.129P2-Agtr2
MGI:87966  MP:0000280 thin ventricular wall PMID: 10930448 
Agtr2tm1Tin Agtr2tm1Tin/Y
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003588 ureter stenosis PMID: 10024874 
Agtr2tm1Tin Agtr2tm1Tin/Agtr2tm1Tin
involves: 129P2/OlaHsd * C57BL/6
MGI:87966  MP:0003588 ureter stenosis PMID: 10024874 
Agtr2tm1Gsb Agtr2tm1Gsb/Y
FVB.129/Sv-Agtr2
MGI:87966  MP:0002975 vascular smooth muscle hypertrophy PMID: 11714657 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Mental retardation, X-linked 88; MRX88
Synonyms: Non-specific X-linked mental retardation [Disease Ontology: DOID:0050776]
X-linked non-syndromic intellectual disability [Orphanet: ORPHA777]
Disease Ontology: DOID:0050776
OMIM: 300852
Orphanet: ORPHA777
Comments: 
References:  7,73,95
Click column headers to sort
Type Species Amino acid change Nucleotide change Description Reference
Frameshift: Deletion Human F133fs 395delT A truncated protein results from base-pair deletion of a thymine nucleotide at position 395 (1-BPDEL, 395T) causing a frameshift at Phe133 in the third transmembrane domain. 95
Missense Human G21V 62G>T 95
Missense Human I53F 157A>T 110
Missense Human R324Q 971G>A 95
Missense Human I337V 1009A>G 95
Biologically Significant Variants Click here for help
Type:  Single nucleotide polymorphism
Species:  Human
Description:  C3123A. The A-allele carriers showed significantly lower high-density lipoprotein cholesterol (HDL-C) levels than the non-A-allele carriers among nonhypertensive subjects. However, this association was not observed among hypertensive subjects. The AT2R A/C3123 polymorphism could be a polymorphic marker related to glycemic control.
Nucleotide change:  3123C>A
References:  5,50
Type:  Single nucleotide polymorphism
Species:  Human
Description:  SNP associated with coronary risk especially in hypertensive patients. The G allele carriers appear protected. A1675G was associated with left ventricular hypertrophy in hypertensive subjects. Left ventricular mass is influenced by the G allele
Nucleotide change:  1675G>A
References:  3,70
Type:  Single nucleotide polymorphism
Species:  Human
Description:  SNP associated with congenital anomalies of the kidney and urinary tract. This however was not confirmed in the pathogenesis of primary familial vesicoureteral reflux
Nucleotide change:  1332A>G
References:  46,66,109,111
Type:  Single nucleotide polymorphism
Species:  Human
Description:  SNP associated with preeclampsia in pregnancies in which the woman had a BMI > 25kg/m(2). This suggests a gene-environment interaction.
Nucleotide change:  4599C>A
References:  115
Biologically Significant Variant Comments
For other AGTR2 SNPs, please see the entry for this gene on dbSNP.
General Comments
The ATGR2 appears to be re-expressed or up-regulated after vascular injury, myocardial infarction, cardiac failure or wound healing, possibly reflecting re-activation of a foetal genetic programme [19-20,37,58]

Preclinical in vitro and in vivo studies indicated that the AT2 receptor counterbalances the effect of the AT1 receptor [19,58,62,64-65].

The most relevant transcription factor binding sites in the AGTR2 gene promoter:
Most relevant TFs: AP-1, ATF-2, IRF-1, CREB, PPAR-γ1, δCREB, PPAR-γ2, c-Jun.

MiRNAs Predicted to Target AGTR2 3’-UTR:
Predicted miRNAs. Both conserved and poorly conserved sites are shown [29,54].

References

Show »

1. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, Ouchi Y, Dzau VJ. (2000) Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics, 2 (1): 13-20. [PMID:11015577]

2. Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ, Horiuchi M. (2000) Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation, 102 (14): 1684-9. [PMID:11015348]

3. Alfakih K, Maqbool A, Sivananthan M, Walters K, Bainbridge G, Ridgway J, Balmforth AJ, Hall AS. (2004) Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. Hypertension, 43 (6): 1189-94. [PMID:15123577]

4. Asada H, Inoue A, Ngako Kadji FM, Hirata K, Shiimura Y, Im D, Shimamura T, Nomura N, Iwanari H, Hamakubo T et al.. (2020) The Crystal Structure of Angiotensin II Type 2 Receptor with Endogenous Peptide Hormone. Structure, 28 (4): 418-425.e4. [PMID:31899086]

5. Ayadi Kabadou I, Soualmiaa H, Jemaa R, Feki M, Kallel A, Souheil O, Haj Taieb S, Sanhaji H, Kaabachi N. (2012) Lack of association between C3123A polymorphism of the angiotensin II type 2 receptor gene and hypertension in Tunisian population. Tunis Med, 90 (8-9): 619-24. [PMID:22987376]

6. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation, 109 (19): 2296-301. [PMID:15117835]

7. Bienvenu T, Poirier K, Van Esch H, Hamel B, Moraine C, Fryns JP, Ropers HH, Beldjord C, Yntema HG, Chelly J. (2003) Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation. J Med Genet, 40 (5): 357-9. [PMID:12746399]

8. Booz GW, Baker KM. (1996) Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension, 28 (4): 635-40. [PMID:8843890]

9. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci, 121 (7): 297-303. [PMID:21542804]

10. Bottari SP, Taylor V, King IN, Bogdal Y, Whitebread S, de Gasparo M. (1991) Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins. Eur J Pharmacol, 207 (2): 157-63. [PMID:1908781]

11. Brechler V, Jones PW, Levens NR, de Gasparo M, Bottari SP. (1993) Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells. Regul Pept, 44 (2): 207-13. [PMID:8385791]

12. Brogelli L, Parenti A, Ledda F. (2002) Inhibition of vascular smooth muscle cell growth by angiotensin type 2 receptor stimulation for in vitro organ culture model. J Cardiovasc Pharmacol, 39 (5): 739-45. [PMID:11973418]

13. Buisson B, Laflamme L, Bottari SP, de Gasparo M, Gallo-Payet N, Payet MD. (1995) A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. J Biol Chem, 270 (4): 1670-4. [PMID:7829501]

14. Carey RM, Wang ZQ, Siragy HM. (2000) Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension, 35 (1 Pt 2): 155-63. [PMID:10642292]

15. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. (2008) Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology, 149 (7): 3452-60. [PMID:18388195]

16. Chang RS, Lotti VJ. (1990) Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol, 37 (3): 347-51. [PMID:2314387]

17. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL et al.. (1989) Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun, 165 (1): 196-203. [PMID:2590220]

18. Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J. (1993) Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol, 110 (2): 761-71. [PMID:8242249]

19. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev, 52 (3): 415-72. [PMID:10977869]

20. de Gasparo M, Siragy HM. (1999) The AT2 receptor: fact, fancy and fantasy. Regul Pept, 81 (1-3): 11-24. [PMID:10395404]

21. de Gasparo M, Whitebread S, Bottari SP, Levens NR. (1994) Heterogeneity of angiotensin receptor subtypes. In Medicinal Chemistry of the Renin-Angiotensin System.. Edited by Timmermanns PBMWM, Wexler RR (Elsevier) 269-294. [ISBN:0444820531]

22. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. (1997) Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res, 81 (6): 970-6. [PMID:9400377]

23. Dudley DT, Panek RL, Major TC, Lu GH, Bruns RF, Klinkefus BA, Hodges JC, Weishaar RE. (1990) Subclasses of angiotensin II binding sites and their functional significance. Mol Pharmacol, 38 (3): 370-7. [PMID:2402226]

24. Dudley DT, Summerfelt RM. (1993) Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells. Regul Pept, 44 (2): 199-206. [PMID:8469774]

25. Esteban V, Lorenzo O, Rupérez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M. (2004) Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol, 15 (6): 1514-29. [PMID:15153562]

26. Esteban V, Ruperez M, Vita JR, López ES, Mezzano S, Plaza JJ, Egido J, Ruiz-Ortega M. (2003) Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl, (86): S33-8. [PMID:12969125]

27. Feng YH, Sun Y, Douglas JG. (2002) Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1. Proc Natl Acad Sci USA, 99 (19): 12049-54. [PMID:12221292]

28. Finnerup NB, Baastrup C. (2014) Angiotensin II: from blood pressure to pain control. Lancet, 383 (9929): 1613-4. [PMID:24507378]

29. Friedman RC, Farh KK, Burge CB, Bartel DP. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19 (1): 92-105. [PMID:18955434]

30. Gallinat S, Yu M, Dorst A, Unger T, Herdegen T. (1998) Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res, 57 (1): 111-22. [PMID:9630555]

31. Gao L, Zucker IH. (2011) AT2 receptor signaling and sympathetic regulation. Curr Opin Pharmacol, 11 (2): 124-30. [PMID:21159555]

32. Gohlke P, Pees C, Unger T. (1998) AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension, 31 (1 Pt 2): 349-55. [PMID:9453327]

33. Haithcock D, Jiao H, Cui XL, Hopfer U, Douglas JG. (1999) Renal proximal tubular AT2 receptor: signaling and transport. J Am Soc Nephrol, 10: S69-S74. [PMID:9892143]

34. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. (1995) Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature, 377 (6551): 744-7. [PMID:7477266]

35. Hein L, Dzau VJ, Barsh GS. (1995) Linkage mapping of the angiotensin AT2 receptor gene (Agtr2) to the mouse X chromosome. Genomics, 30: 369-371. [PMID:8586443]

36. Herradon G, Ezquerra L, Nguyen T, Vogt TF, Bronson R, Silos-Santiago I, Deuel TF. (2004) Pleiotrophin is an important regulator of the renin-angiotensin system in mouse aorta. Biochem Biophys Res Commun, 324 (3): 1041-7. [PMID:15485659]

37. Horiuchi M, Akishita M, Dzau VJ. (1999) Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension, 33 (2): 613-21. [PMID:10024316]

38. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. (1997) Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem, 272 (30): 19022-6. [PMID:9228085]

39. Horiuchi M, Lehtonen JY, Daviet L. (1999) Signaling Mechanism of the AT2 Angiotensin II Receptor: Crosstalk between AT1 and AT2 Receptors in Cell Growth. Trends Endocrinol Metab, 10 (10): 391-396. [PMID:10542395]

40. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. (2002) Targeted deletion of angiotensin II type 2 receptor caused cardiac ruptureafter acute myocardial infarction. Circulation, 106: 2244-2249. [PMID:12390955]

41. Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney FA, Inagami T. (2001) Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation, 104 (3): 346-51. [PMID:11457756]

42. Ichiki T, Inagami T. (1995) Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene. Circ Res, 76 (5): 693-700. [PMID:7728985]

43. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. (1995) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature, 377 (6551): 748-50. [PMID:7477267]

44. Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN et al.. (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol, 27 (2): 297-302. [PMID:17138938]

45. Jin XQ, Fukuda N, Su JZ, Lai YM, Suzuki R, Tahira Y, Takagi H, Ikeda Y, Kanmatsuse K, Miyazaki H. (2002) Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertension, 39 (5): 1021-7. [PMID:12019286]

46. Jones A, Dhamrait SS, Payne JR, Hawe E, Li P, Toor IS, Luong L, Wootton PT, Miller GJ, Humphries SE et al.. (2003) Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension, 42 (4): 500-6. [PMID:12925562]

47. Katada J, Majima M. (2002) AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol, 136 (4): 484-91. [PMID:12055126]

48. Kim NH, Ahn Y, Oh SK, Cho JK, Park HW, Kim YS, Hong MH, Nam KI, Park WJ, Jeong MH et al.. (2005) Altered patterns of gene expression in response to chronic atrial fibrillation. Int Heart J, 46 (3): 383-95. [PMID:16043935]

49. Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, Dzau VJ. (1994) Human type 2 angiotensin II receptor genecloned, mapped to the x chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun, 203: 1842-1850. [PMID:7945336]

50. Kotani K, Sakane N, Taniguchi N. (2013) Association between angiotensin II Type 2 receptor gene A/C3123 polymorphism and high-density lipoprotein cholesterol with hypertension in asymptomatic women. Med Princ Pract, 22 (1): 65-9. [PMID:22869520]

51. Krause LMH, Kemp BA, Tan ASJ, Jones ES, Del Borgo MP, Aguilar MI, Denton KM, Carey RM, Widdop RE. (2020) Renal functional effects of the highly selective AT2R agonist, β-Pro7 Ang III, in normotensive rats. Clin Sci (Lond.), 134 (7): 871-884. [PMID:32202299]

52. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O et al.. (2003) Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension, 41 (1): 99-107. [PMID:12511537]

53. Leung KH, Smith RD, Timmermans BM, Chiu AT. (1991) Regional distribution of the two subtypes of angiotensin II receptor in ratbrain using selective nonpeptide antagonists. Neurosci Lett, 123: 95-98. [PMID:2062460]

54. Lewis BP, Burge CB, Bartel DP. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120 (1): 15-20. [PMID:15652477]

55. Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, Katovich MJ, Sumners C. (2009) Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther, 8 (12): 3255-65. [PMID:19996275]

56. Lokuta AJ, Cooper C, Gaa ST, Wang HE, Rogers TB. (1994) Angiotensin II stimulates the release of phospholipid-derived second messengersthrough multiple receptor subtypes in heart cells. J Biol Chem, 269: 4832-4838. [PMID:8106454]

57. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. (1998) The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med, 188 (4): 661-70. [PMID:9705948]

58. Matsubara H. (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res, 83 (12): 1182-91. [PMID:9851935]

59. Menk M, Graw JA, von Haefen C, Sifringer M, Schwaiberger D, Unger T, Steckelings U, Spies CD. (2015) Stimulation of the Angiotensin II AT2 Receptor is Anti-inflammatory in Human Lipopolysaccharide-Activated Monocytic Cells. Inflammation, 38 (4): 1690-9. [PMID:25758542]

60. Mertens B, Vanderheyden P, Michotte Y, Sarre S. (2010) Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum. Neuropharmacology, 58 (7): 1038-44. [PMID:20097214]

61. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T. (2000) Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension, 36 (5): 845-50. [PMID:11082154]

62. Millatt LJ, Abdel-Rahman EM, Siragy HM. (1999) Angiotensin II and nitric oxide: a question of balance. Regul Pept, 81 (1-3): 1-10. [PMID:10395403]

63. Miura S, Karnik SS. (2000) Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J, 19 (15): 4026-35. [PMID:10921883]

64. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. (1995) The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA, 92 (23): 10663-7. [PMID:7479861]

65. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A. (1999) Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension, 33 (2): 719-25. [PMID:10024335]

66. Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, Yoshida H, Ichiki T, Threadgill D, Phillips 3rd JA et al.. (1999) Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell, 3 (1): 1-10. [PMID:10024874]

67. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M et al.. (2004) Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem, 279 (28): 28989-97. [PMID:15123706]

68. Nouet S, Nahmias C. (2000) Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab, 11 (1): 1-6. [PMID:10652498]

69. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y et al.. (1997) Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation, 96 (11): 3954-62. [PMID:9403620]

70. Ott C, Titze SI, Schwarz TK, Kreutz R, Hilgers KF, Schmidt BM, Schlaich MP, Schmieder RE. (2007) High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. J Hypertens, 25 (8): 1627-32. [PMID:17620959]

71. Petracco RG, Kong A, Grechukhina O, Krikun G, Taylor HS. (2012) Global gene expression profiling of proliferative phase endometrium reveals distinct functional subdivisions. Reprod Sci, 19 (10): 1138-45. [PMID:22623515]

72. Porrello ER, D'Amore A, Curl CL, Allen AM, Harrap SB, Thomas WG, Delbridge LM. (2009) Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension, 53 (6): 1032-40. [PMID:19433781]

73. Renieri A, Pescucci C, Longo I, Ariani F, Mari F, Meloni I. (2005) Non-syndromic X-linked mental retardation: from a molecular to a clinical point of view. J Cell Physiol, 204 (1): 8-20. [PMID:15690397]

74. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N et al.. (2014) EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet, 383 (9929): 1637-47. [PMID:24507377]

75. Saavedra JM, Armando I, Terrón JA, Falcón-Neri A, Jöhren O, Häuser W, Inagami T. (2001) Increased AT(1) receptors in adrenal gland of AT(2) receptor gene-disrupted mice. Regul Pept, 102 (1): 41-7. [PMID:11600209]

76. Senbonmatsu T, Saito T, Landon EJ, Watanabe O, Price Jr E, Roberts RL, Imboden H, Fitzgerald TG, Gaffney FA, Inagami T. (2003) A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J, 22 (24): 6471-82. [PMID:14657020]

77. Seyedi N, Xu X, Nasjletti A, Hintze TH. (1995) Coronary kinin generation mediates nitric oxide release after angiotensinreceptor stimulation. Hypertension, 26: 164-170. [PMID:7607720]

78. Sharma N, Belenchia AM, Toedebusch R, Pulakat L, Hans CP. (2020) AT2R agonist NP-6A4 mitigates aortic stiffness and proteolytic activity in mouse model of aneurysm. J Cell Mol Med, 24 (13): 7393-7404. [PMID:32420690]

79. Siragy HM, Carey RM. (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest, 100 (2): 264-9. [PMID:9218502]

80. Siragy HM, de Gasparo M, Carey RM. (2000) Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension, 35 (5): 1074-7. [PMID:10818067]

81. Siragy HM, Inagami T, Ichiki T, Carey RM. (1999) Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA, 96 (11): 6506-10. [PMID:10339618]

82. Smith GR, Missailidis S. (2004) Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond.), 1 (1): 3. [PMID:15813980]

83. Smith MT, Wyse BD, Edwards SR. (2013) Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med, 14 (5): 692-705. [PMID:23489258]

84. Smith RD, Timmermans PB. (1994) Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens, 3 (1): 112-22. [PMID:7850406]

85. Smith S, Ramirez VD. (2002) Direct visualization of internalization and intracellular trafficking of dopamine-releasing protein-36aa. Neuroendocrinology, 75 (2): 98-112. [PMID:11867938]

86. Speth RC, Kim KH. (1990) Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II. Biochem Biophys Res Commun, 169 (3): 997-1006. [PMID:2194459]

87. Stoll M, Steckelings UM, Bottari SP, Paul M, Metzger R, Unger T. (1995) The Angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest, 95: 651-657. [PMID:7860748]

88. Tamura M, Wanaka Y, Landon EJ, Inagami T. (1999) Intracellular sodium modulates the expression of angiotensin II subtype 2 receptor in PC12W cells. Hypertension, 33 (2): 626-32. [PMID:10024318]

89. Tanaka M, Tsuchida S, Imai T, Fujii N, Miyazaki H, Ichiki T, Naruse M, Inagami T. (1999) Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. Biochem Biophys Res Commun, 258 (1): 194-8. [PMID:10222259]

90. Tissir F, Rivière M, Guo DF, Tsuzuki S, Inagami T, Levan G, Szpirer J, Szpirer C. (1995) Localization of the genes encoding the three rat angiotensin II receptors, Agtr1a, Agtr1b, Agtr2, and the human AGTR2 receptor respectively to rat chromosomes 17q12, 2q24 and Xq34, and the human Xq22. Cytogenet Cell Genet, 71 (1): 77-80. [PMID:7606933]

91. Tsutsumi K, Saavedra JM. (1991) Differential development of angiotensin II receptor subtypes in the rat brain. Endocrinology, 128 (1): 630-2. [PMID:1986946]

92. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K et al.. (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest, 104 (7): 925-35. [PMID:10510333]

93. van Kesteren CA, van Heugten HA, Lamers JM, Saxena PR, Schalekamp MA, Danser AH. (1997) Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol, 29 (8): 2147-57. [PMID:9281446]

94. Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R, Roks AJ, Danser AH, van Esch JH. (2012) Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension, 60 (3): 722-9. [PMID:22802221]

95. Vervoort VS, Beachem MA, Edwards PS, Ladd S, Miller KE, de Mollerat X, Clarkson K, DuPont B, Schwartz CE, Stevenson RE et al.. (2002) AGTR2 mutations in X-linked mental retardation. Science, 296 (5577): 2401-3. [PMID:12089445]

96. Whitebread S, Mele M, Kamber B, de Gasparo M. (1989) Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun, 163 (1): 284-91. [PMID:2775266]

97. Whitebread SE, Taylor V, Bottari SP, Kamber B, de Gasparo M. (1991) Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. Biochem Biophys Res Commun, 181 (3): 1365-71. [PMID:1764088]

98. Wiemer G, Schölkens BA, Wagner A, Heitsch H, Linz W. (1993) The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens Suppl, 11 (5): S234-5. [PMID:8158361]

99. Wiest SA, Rampersaud A, Zimmerman K, Steinberg MI. (1991) Characterization of distinct angiotensin II binding sites in rat adrenal gland and bovine cerebellum using selective nonpeptide antagonists. J Cardiovasc Pharmacol, 17 (2): 177-84. [PMID:1709220]

100. Wu L, Iwai M, Li Z, Shiuchi T, Min LJ, Cui TX, Li JM, Okumura M, Nahmias C, Horiuchi M. (2004) Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol, 18 (3): 666-78. [PMID:14684844]

101. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M. (2001) Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation, 104 (22): 2716-21. [PMID:11723025]

102. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP. (2002) Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension, 40 (3): 244-50. [PMID:12215461]

103. Yamada H, Akishita M, Ito M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ, Horiuchi M. (1999) AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension, 33 (6): 1414-9. [PMID:10373225]

104. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. (1998) Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci, 63 (19): PL289-95. [PMID:9806232]

105. Yamada T, Horiuchi M, Dzau VJ. (1996) Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA, 93 (1): 156-60. [PMID:8552595]

106. Yamada Y, Yamauchi D, Usui H, Zhao H, Yokoo M, Ohinata K, Iwai M, Horiuchi M, Yoshikawa M. (2008) Hypotensive activity of novokinin, a potent analogue of ovokinin(2-7), is mediated by angiotensin AT(2) receptor and prostaglandin IP receptor. Peptides, 29 (3): 412-8. [PMID:18207609]

107. Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G, Lukaszuk A, Tourwé D, Chai SY, Albiston AL et al.. (2011) Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent. Hypertension, 57 (5): 956-64. [PMID:21464395]

108. Yang Z, Bove CM, French BA, Epstein FH, Berr SS, DiMaria JM, Gibson JJ, Carey RM, Kramer CM. (2002) Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation, 106 (1): 106-11. [PMID:12093778]

109. Yerkes E, Nishimura H, Miyazaki Y, Tsuchida S, Brock 3rd JW, Ichikawa I. (1998) Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. Kidney Int Suppl, 67: S75-7. [PMID:9736258]

110. Ylisaukko-oja T, Rehnström K, Vanhala R, Tengström C, Lähdetie J, Järvelä I. (2004) Identification of two AGTR2 mutations in male patients with non-syndromic mental retardation. Hum Genet, 114 (2): 211-3. [PMID:14598163]

111. Yoneda A, Cascio S, Green A, Barton D, Puri P. (2002) Angiotensin II type 2 receptor gene is not responsible for familial vesicoureteral reflux. J Urol, 168 (3): 1138-41. [PMID:12187255]

112. Yu L, Shao C, Gao L. (2014) Developmental expression patterns for angiotensin receptors in mouse skin and brain. J Renin Angiotensin Aldosterone Syst, 15 (2): 139-49. [PMID:23204186]

113. Zhang J, Pratt RE. (1996) The AT2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. J Biol Chem, 271 (25): 15026-33. [PMID:8663053]

114. Zhao Y, Biermann T, Luther C, Unger T, Culman J, Gohlke P. (2003) Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. J Neurochem, 85 (3): 759-67. [PMID:12694402]

115. Zhou A, Dekker GA, Lumbers ER, Lee SY, Thompson SD, McCowan LM, Roberts CT, SCOPE consortium. (2013) The association of AGTR2 polymorphisms with preeclampsia and uterine artery bilateral notching is modulated by maternal BMI. Placenta, 34 (1): 75-81. [PMID:23122839]

116. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, Yang XP. (2010) Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension, 56 (3): 384-90. [PMID:20606103]

117. Zhu M, Natarajan R, Nadler JL, Moore JM, Gelband CH, Sumners C. (2000) Angiotensin II increases neuronal delayed rectifier K(+) current: role of 12-lipoxygenase metabolites of arachidonic acid. J Neurophysiol, 84 (5): 2494-501. [PMID:11067992]

Contributors

Show »

How to cite this page